Skin Squamous Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: SKN022 MIFTS: 61	Skin Squamous Cell Carcinoma Categories: Cancer diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Skin Squamous Cell Carcinoma

MalaCards integrated aliases for Skin Squamous Cell Carcinoma:

Name: Skin Squamous Cell Carcinoma ¹¹ ¹⁴

Squamous Cell Carcinoma of Skin ¹¹ ⁷¹ ³³

Scc - [squamous Cell Carcinoma] of Skin ³³

Squamous Cell Carcinoma of the Skin ⁵

Squamous Cell Epithelioma of Skin ³³

Cutaneous Squamous Cell Carcinoma ³³

Epidermoid Skin Carcinoma ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Skin diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Neoplasms

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms of skin

Squamous cell carcinoma of skin

External Ids:

Disease Ontology ¹¹ DOID:3151

NCIt ⁴⁹ C4819

SNOMED-CT ⁶⁸ 254651007

ICD11 ³³ 1448983042

UMLS ⁷¹ C0553723

Sources

Summaries for Skin Squamous Cell Carcinoma

Disease Ontology: ¹¹ A skin carcinoma that has material basis in squamous cells.

MalaCards based summary: Skin Squamous Cell Carcinoma, also known as squamous cell carcinoma of skin, is related to squamous cell carcinoma and keratoacanthoma. An important gene associated with Skin Squamous Cell Carcinoma is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are Disease and GPCR Pathway. The drugs Carboplatin and Panitumumab have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and lung, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

Sources

Related Diseases for Skin Squamous Cell Carcinoma

Diseases related to Skin Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 684)

#	Related Disease	Score	Top Affiliating Genes
1	squamous cell carcinoma	31.4	TP53 NRAS KDM4C HRAS HOTAIR ERBB2
2	keratoacanthoma	31.1	TP53 MSH2 MLH1
3	keratinizing squamous cell carcinoma	30.9	TP53 HRAS CDKN2A
4	skin carcinoma	30.9	TP53 NRAS MSH2 MIR21 KDM4C HRAS
5	thyroid cancer, nonmedullary, 1	30.7	TP53 HOTAIR BRAF
6	basal cell nevus syndrome	30.7	TP53 KDM4C HRAS
7	hematologic cancer	30.6	MSH2 MLH1 MIR21 KDM4C HRAS
8	ocular melanoma	30.6	NRAS HRAS CDKN2A
9	salivary gland carcinoma	30.6	TP53 ERBB2 CDKN2A
10	oropharynx cancer	30.6	TP53 MIR21 HRAS ERBB2 CDKN2A
11	human papillomavirus infectious disease	30.6	TP53 MIR21 HRAS ERBB2 CDKN2A
12	suppressor of tumorigenicity 3	30.5	TP53 CDKN2A
13	laryngeal benign neoplasm	30.5	TP53 CDKN2A BCL2L12
14	actinic keratosis	30.5	TP53 KNSTRN CDKN2A
15	lung benign neoplasm	30.5	TP53 HRAS CDKN2A
16	appendix adenocarcinoma	30.5	TP53 MSH6 HRAS
17	neurofibroma	30.5	TP53 RAC1 ERBB2 CDKN2A
18	pancreatic ductal carcinoma	30.4	TP53 HRAS ERBB2 CDKN2A
19	head and neck cancer	30.4	TP53 MIR21 KDM4C HRAS FAT2 ERBB2
20	leukemia, chronic lymphocytic	30.4	TP53 NRAS MIR21 LRRC56 KDM4C HRAS
21	breast adenocarcinoma	30.4	TP53 HRAS ERBB2 CDKN2A
22	small cell cancer of the lung	30.4	TP53 MIR21 HOTAIR CDKN2A
23	nevus, epidermal	30.4	NRAS LRRC56 HRAS
24	langerhans cell histiocytosis	30.4	NRAS HRAS BRAF
25	brain glioma	30.4	TP53 KDM4C ERBB2 CDKN2A
26	thymoma	30.4	TP53 LRRC56 HRAS CDKN2A
27	sebaceous adenoma	30.3	MSH6 MSH2 MLH1
28	mismatch repair cancer syndrome 1	30.3	MSH6 MSH2 MLH1
29	leukemia, acute lymphoblastic	30.3	TP53 MSH2 MIR21 KDM4C HRAS CDKN2A
30	adenoid cystic carcinoma	30.3	TP53 LRRC56 HRAS ERBB2 CDKN2A
31	lynch syndrome 1	30.3	MSH6 MSH2 MLH1
32	lentigines	30.3	RAF1 MSH2 MLH1 BRAF
33	skin benign neoplasm	30.3	TP53 MSH6 MSH2 MLH1 HRAS BRAF
34	leukemia	30.3	TP53 RAF1 NRAS HOTAIR ERBB2 CDKN2A
35	pancreatic ductal adenocarcinoma	30.3	TP53 MIR21 KDM4C HRAS HOTAIR
36	meningioma, familial	30.3	TP53 RAC1 HRAS ERBB2 CDKN2A
37	adenocarcinoma	30.2	TP53 MSH6 MSH2 MLH1 HRAS ERBB2
38	connective tissue disease	30.2	TP53 MIR21 KDM4C HRAS ERBB2 CDKN2A
39	colon adenocarcinoma	30.2	TP53 MSH6 MLH1 HRAS BRAF
40	inherited cancer-predisposing syndrome	30.2	TP53 MSH6 MSH2 MLH1 CDKN2A
41	bap1 tumor predisposition syndrome	30.2	TP53 MSH6 MSH2 MLH1 CDKN2A
42	leukemia, acute myeloid	30.1	TP53 NRAS MIR21 LRRC56 KDM4C HRAS
43	myeloma, multiple	30.1	TP53 NRAS MIR21 LRRC56 KDM4C HRAS
44	muir-torre syndrome	30.1	TP53 MSH6 MSH2 MLH1 HRAS CDKN2A
45	leukemia, chronic myeloid	30.0	TP53 RAF1 NRAS KDM4C HRAS HOTAIR
46	lymphoma, non-hodgkin, familial	30.0	TP53 NRAS MSH2 MIR21 KDM4C BRAF
47	neurofibromatosis	30.0	TP53 NRAS MSH6 MSH2 MLH1 HRAS
48	skin disease	30.0	TP53 NRAS MIR21 KDM4C HRAS ERBB2
49	mucinous adenocarcinoma	30.0	TP53 MSH6 MSH2 MLH1 HRAS ERBB2
50	serous cystadenocarcinoma	30.0	TP53 MSH6 MSH2 MLH1 MIR21 HRAS

Graphical network of the top 20 diseases related to Skin Squamous Cell Carcinoma:

Sources

Symptoms & Phenotypes for Skin Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

²⁵ (show all 21)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	10.42	BRAF STK19 HRAS
2	Decreased viability	GR00055-A-2	10.42	BRAF STK19 HRAS
3	Decreased viability	GR00221-A-1	10.42	RAF1 CDKN2A HRAS NRAS
4	Decreased viability	GR00221-A-2	10.42	RAF1 STK19 HRAS
5	Decreased viability	GR00221-A-3	10.42	STK19 CDKN2A ERBB2 HRAS NRAS
6	Decreased viability	GR00221-A-4	10.42	BRAF STK19 CDKN2A ERBB2
7	Decreased viability	GR00249-S	10.42	BRAF
8	Decreased viability	GR00301-A	10.42	BRAF MSH2 RAF1 STK19
9	Decreased viability	GR00381-A-1	10.42	BRAF
10	Decreased viability	GR00402-S-2	10.42	RAF1 STK19
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-116	9.44	RAF1
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-149	9.44	BRAF
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-150	9.44	KDM4C RAF1
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-151	9.44	RAF1
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-188	9.44	KDM4C
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-209	9.44	KDM4C
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-3	9.44	NRAS
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-47	9.44	BRAF
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-52	9.44	RAF1
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-72	9.44	KDM4C NRAS RAF1
21	Increased cell migration	GR00055-A-3	8.65	STK19

MGI Mouse Phenotypes related to Skin Squamous Cell Carcinoma:

⁴⁵ (show all 11)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.3	BRAF CDKN2A ERBB2 HRAS KDM4C KNSTRN
2	neoplasm	MP:0002006	10.24	BRAF CDKN2A ERBB2 HRAS KDM4C MLH1
3	endocrine/exocrine gland	MP:0005379	10.17	BRAF CDKN2A ERBB2 HRAS KDM4C KNSTRN
4	cellular	MP:0005384	10.1	BRAF CDKN2A ERBB2 KDM4C KNSTRN MLH1
5	immune system	MP:0005387	10.03	BCL2L12 BRAF CDKN2A KDM4C LRRC56 MLH1
6	no phenotypic analysis	MP:0003012	10.02	CDKN2A HOTAIR HRAS KDM4C NRAS RAF1
7	digestive/alimentary	MP:0005381	10.01	BRAF CDKN2A ERBB2 HRAS MLH1 MSH2
8	craniofacial	MP:0005382	9.91	BRAF ERBB2 HRAS NRAS RAC1 RAF1
9	hematopoietic system	MP:0005397	9.77	BCL2L12 BRAF CDKN2A ERBB2 KDM4C KNSTRN
10	respiratory system	MP:0005388	9.76	BRAF CDKN2A ERBB2 HRAS LRRC56 MLH1
11	integument	MP:0010771	9.44	BRAF CDKN2A ERBB2 HRAS KDM4C LRRC56

Sources

Drugs & Therapeutics for Skin Squamous Cell Carcinoma

Drugs for Skin Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Panitumumab

Approved, Investigational

Phase 2

339177-26-3

Peginterferon alfa-2b

Approved

Phase 2

215647-85-1, 99210-65-8

Peginterferon alfa-2a

Approved, Investigational

Phase 2

198153-51-4

Pioglitazone

Approved, Investigational

Phase 2

111025-46-8

4829

Dasatinib

Approved, Investigational

Phase 2

302962-49-8

3062316

Gefitinib

Approved, Investigational

Phase 2

184475-35-2

123631

Ethanol

Approved

Phase 2

64-17-5

702

Hydrogen peroxide

Approved, Vet_approved

Phase 2

7722-84-1

784

Talimogene laherparepvec

Approved, Experimental, Investigational

Phase 2

1187560-31-1

Ipilimumab

Approved

Phase 2

477202-00-9

Avelumab

Approved, Investigational

Phase 2

1537032-82-8

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Afatinib

Approved

Phase 2

439081-18-2, 850140-72-6

53445376 10184653

Atezolizumab

Approved, Investigational

Phase 2

1380723-44-3

Nivolumab

Approved

Phase 2

946414-94-4

Cetuximab

Approved

Phase 2

205923-56-4

Fluorouracil

Approved

Phase 2

51-21-8

3385

Calcipotriol

Approved

Phase 2

112965-21-6

5288783

Doxorubicin

Approved, Investigational

Phase 1, Phase 2

23214-92-8

31703

Petrolatum

Approved, Investigational

Phase 2

8009-03-8

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Pembrolizumab

Approved

Phase 1, Phase 2

1374853-91-4

254741536

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 2

133585-56-5, 60-18-4, 556-02-5

1153 6057

Cholecalciferol

Approved, Nutraceutical, Vet_approved

Phase 2

67-97-0, 1406-16-2

5280795 10883523

Calcitriol

Approved, Nutraceutical

Phase 2

32222-06-3

5280453

Vilobelimab

Investigational

Phase 2

2250440-41-4

Antiviral Agents

Phase 2

Interferon alpha-2

Phase 2

Interferon-alpha

Phase 2

ON 01910

Phase 2

Anti-Infective Agents

Phase 2

Anti-Infective Agents, Local

Phase 2

Immune Checkpoint Inhibitors

Phase 2

Adjuvants, Immunologic

Phase 1, Phase 2

Monatide (IMS 3015)

Phase 1, Phase 2

Analgesics

Phase 1, Phase 2

Complement System Proteins

Phase 2

Interleukin-2

Phase 1, Phase 2

Analgesics, Non-Narcotic

Phase 1, Phase 2

Antibodies, Blocking

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Pharmaceutical Solutions

Phase 1, Phase 2

Antibodies, Monoclonal

Phase 2

Immunoglobulins, Intravenous

Phase 2

Immunoglobulin G

Phase 2

Immunosuppressive Agents

Phase 2

Immunologic Factors

Phase 2

Hormones

Phase 2

Interventional clinical trials:

(show top 50) (show all 146)

#	Name	Status	NCT ID	Phase	Drugs
1	Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck	Completed	NCT00193895	Phase 3	Carboplatin
2	A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)	Recruiting	NCT03833167	Phase 3	Placebo
3	A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma	Recruiting	NCT03969004	Phase 3	Cemiplimab;Placebo
4	A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin	Unknown status	NCT00423397	Phase 1, Phase 2	gefitinib
5	A Phase II of Study of Nivolumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma	Unknown status	NCT03834233	Phase 2	Nivolumab
6	An Open Label Multicentric Phase II Study of Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC)	Unknown status	NCT01129154	Phase 2	infusions of Panitumumab
7	A Phase 2 Study of Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma	Completed	NCT02218164	Phase 2	Pegylated Interferon alpha-2b;Capecitabine;5-FU
8	Phase II Study of Erlotinib, An Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin	Completed	NCT01198028	Phase 2	Erlotinib
9	A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma	Completed	NCT01807546	Phase 2	rigosertib
10	Chemoprevention of Squamous Cell Cancer of the Skin in High Risk Patients	Completed	NCT02347813	Phase 2	Pioglitazone
11	A Phase 2 Study of Dasatinib in Patients With Transplant and Non-Transplant Related Unresectable or Metastatic Cutaneous Squamous Cell Carcinoma and RAI Stage 0-1 Chronic Lymphocytic Leukemia	Completed	NCT00563290	Phase 2	dasatinib
12	A Phase IIb Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Topical Bacteriophage T4 Endonuclease V in Renal Allograft Recipients With a History of Non-melanoma Skin Cancer	Completed	NCT00089180	Phase 2	liposomal T4N5 lotion
13	A Phase II Study of ZD1839 and Radiation in Patients With Squamous Cell Carcinoma of the Skin	Completed	NCT00126555	Phase 2	Gefitinib
14	A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin	Completed	NCT00054691	Phase 2	Iressa
15	Phase II Study of Cetuximab as Monotherapy and First Line Treatment in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Expressing EGFR.	Completed	NCT00240682	Phase 2	cetuximab
16	Phase II Study of Pembrolizumab (MK-3475) as First Line Single Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin	Completed	NCT02883556	Phase 2	Pembrolizumab
17	An Open Phase II Study to Assess the Efficacy and Safety of Topical SR-T100® Gel in the Treatment of Human Cutaneous Squamous Cell Carcinoma in Situ (Actinic Keratosis and Bowen's Disease)	Completed	NCT02085395	Phase 2	SR-T100 ® Gel
18	An Open-Label Safety Study of API 31510 in a Topical Cream for in Situ Cutaneous Squamous Cell Carcinoma (SCCIS)	Completed	NCT00652080	Phase 1, Phase 2	API 31510
19	An Open Label, Dose Escalation Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Patients With Cutaneous Squamous Cell Carcinoma in Situ (isSCC)	Completed	NCT04293679	Phase 1, Phase 2	STP705
20	Multi-centre, Open-label Study to Determine the Safety and Efficacy of PEP005 0.05% Topical Gel in Patients With Cutaneous Squamous Cell Carcinoma In Situ (SCCIS, Bowen's Disease)	Completed	NCT00329121	Phase 2	PEP005
21	A Phase 2 Study of ALKS 4230 in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Advanced or Recurrent Head and Neck Squamous Cell Cancer Currently on Treatment With Anti-PD-(L)1 Without Having Achieved a Complete Remission	Completed	NCT04144517	Phase 2	ALKS 4230;Pembrolizumab
22	A Phase 2 Double-blind Placebo Randomized Controlled Trial of 30% Topical Application of Hydrogen Peroxide as Neoadjuvant Treatment of Non-melanoma Skin Cancers Prior to Definitive Surgery or Radiation	Recruiting	NCT04929535	Phase 2	Hydrogen Peroxide 30 % Topical Solution
23	A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors	Recruiting	NCT02978625	Phase 2
24	Evaluating the PD-1 Checkpoint Inhibitor, Cemiplimab, as Neoadjuvant Therapy in High Risk Localized, Locally Recurrent, and Regionally Advanced Cutaneous Squamous Cell Carcinoma: A Phase II Pilot Study	Recruiting	NCT04315701	Phase 2
25	A Phase II, Multicenter, Single-Arm Clinical Trial of Radiotherapy and CeMiPlimAb: Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: RAMPART	Recruiting	NCT05574101	Phase 2	Cemiplimab
26	Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)	Recruiting	NCT03944941	Phase 2	Avelumab;Cetuximab
27	UNresectable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy. A Study to Evaluate the Efficacy and Safety of the Combined Use of Avelumab With Radiation Therapy for the Treatment of Unresectable Cutaneous Squamous Cell Carcinoma	Recruiting	NCT03737721	Phase 2
28	Camrelizumab Plus Cisplatin in Advanced Cutaneous Squamous Cell Carcinoma: a Single-arm, Open, Single-center Phase II Study	Recruiting	NCT05490485	Phase 2	Camrelizumab
29	Phase II Study of REGN2810 Prior to Surgery in Patients With Stage II-IV Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck	Recruiting	NCT03565783	Phase 2
30	A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma	Recruiting	NCT04050436	Phase 2	Cemiplimab
31	Neo-Adjuvant Atezolizumab Prior to Definitive Surgical Resection of Regionally Metastatic Head &Amp; Neck Cutaneous Squamous Cell Carcinoma With an Unknown or Historic Primary Site: A Window Trial	Recruiting	NCT05110781	Phase 2
32	An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors	Recruiting	NCT04305795	Phase 1, Phase 2
33	A Phase I/II Basket Trial of the EGF Vaccine CIMAvax in Combination With Anti-PD1 Therapy in Patients With Advanced NSCLC or Squamous Head and Neck Cancer	Recruiting	NCT02955290	Phase 1, Phase 2
34	Quad-Shot Radiotherapy in Combination With Immune Checkpoint Inhibition for Advanced/Recurrent Head and Neck Cancer	Recruiting	NCT04454489	Phase 2	Pembrolizumab (immunotherapy)
35	Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Patients Prior to Standard of Care Surgery; the MATISSE Trial	Recruiting	NCT04620200	Phase 2	Nivolumab;Ipilimumab
36	ML42362: Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma	Recruiting	NCT04710498	Phase 2	Atezolizumab
37	Open Label, Multicenter Phase II Study of the C5a Antibody IFX-1 Alone or IFX-1 + Pembrolizumab in Patients With PD-1 or PD-L1 Resistant/Refractory Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC)	Recruiting	NCT04812535	Phase 2	IFX-1;IFX-1 + pembrolizumab combination therapy
38	Phase II Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)	Recruiting	NCT04808999	Phase 2	Pembrolizumab Injection
39	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Patients With Cutaneous Squamous Cell Carcinoma in Situ (isSCC)	Recruiting	NCT04844983	Phase 2	STP705
40	A Multi-Center Phase II Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma	Recruiting	NCT04807777	Phase 2	Ruxolitinib
41	A Single-arm, Open-Label, Multicenter Phase II Clinical Study to Evaluate Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) in Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)	Recruiting	NCT05238363	Phase 2	HLX07
42	Phase 2, Open-label, Single-arm, Window of Opportunity Study of ASP-1929 Photoimmunotherapy With Fluorescence Imaging in Patients With Operable Primary or Recurrent Head and Neck or Cutaneous Squamous Cell Carcinoma	Recruiting	NCT05182866	Phase 2
43	Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma	Recruiting	NCT05070403	Phase 2	Afatinib 40 MG
44	An Open Label, Dose Escalation Study to Evaluate the Safety and Efficacy of Intralesional Injection of STP705 in Adult Subjects With Facial Cutaneous Squamous Cell Carcinoma in Situ (isSCC)	Recruiting	NCT05421013	Phase 1, Phase 2	STP705
45	A Phase 2 Study of De-escalation in Resectable, Locally Advanced Cutaneous Squamous Cell Carcinoma With the Use of Neoadjuvant Pembrolizumab - DESQUAMATE	Recruiting	NCT05025813	Phase 2	Pembrolizumab
46	A Phase 1/2a, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas	Recruiting	NCT05565417	Phase 1, Phase 2	IMT-009
47	A Phase 1b/2a, Open Label Study to Evaluate Anti-tumor Efficacy and Safety of rhIL-7-hyFc (NT-I7) in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Anti-PD-1/PD-L1 naïve or Relapsed/Refractory High-risk Skin Cancers	Recruiting	NCT03901573	Phase 1, Phase 2	NT-I7;atezolizumab
48	A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors	Recruiting	NCT04301011	Phase 1, Phase 2
49	A Phase II, Single Arm Study Investigating Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in High Risk, Surgically Resectable, Stage III Cutaneaous Squamous Cell Carcinoma	Recruiting	NCT04632433	Phase 2	Cemiplimab
50	A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 Monotherapy or in Combination With Cetuximab as a Salvage Regimen for Solid Tumors	Recruiting	NCT04616196	Phase 1, Phase 2	NKTR-255;Cetuximab

Search NIH Clinical Center for Skin Squamous Cell Carcinoma

Sources

Genetic Tests for Skin Squamous Cell Carcinoma

Sources

Anatomical Context for Skin Squamous Cell Carcinoma

Organs/tissues related to Skin Squamous Cell Carcinoma:

MalaCards : Skin, Lymph Node, Lung, Kidney, Breast, Thyroid, Liver

Sources

Publications for Skin Squamous Cell Carcinoma

Articles related to Skin Squamous Cell Carcinoma:

(show top 50) (show all 4070)

#	Title	Authors	PMID	Year
1	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. ⁵	Chang MT...Taylor BS	26619011	2016
2	Prospective enterprise-level molecular genotyping of a cohort of cancer patients. ⁵	MacConaill LE...Lindeman NI	25157968	2014
3	Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. ⁵	Anforth R...Fernandez-Penas P	22726224	2012
4	RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. ⁵	Su F...Marais R	22256804	2012
5	Thirteen cancers associated with HIV infection in a Black South African cancer patient population (1995-2016). ⁶²	Sengayi-Muchengeti M...Sitas F	36054877	2023
6	Gallic acid has an inhibitory effect on skin squamous cell carcinoma and acts on the heat shock protein HSP90AB1. ⁶²	de Jesus SF...Guimaraes ALS	36375658	2023
7	Squamous Cell Carcinoma: An Update in Staging, Management, and Postoperative Surveillance Strategies. ⁶²	Guzman AK...Ruiz ES	36410970	2023
8	Pristimerin mediated anticancer effects and sensitization of human skin cancer cells through modulation of MAPK signaling pathways. ⁶²	Al-Tamimi M...Uddin S	36411635	2022
9	Epidemiology and treatment outcomes of cutaneous squamous cell carcinoma extending to the temporal bone. ⁶²	Schachtel MJC...Panizza BJ	36082824	2022
10	Prospective study evaluating the personal history of rosacea and risk of cutaneous squamous cell carcinoma among women in the United States. ⁶²	Lin EM...Cho E	36089188	2022
11	Are YouTube videos on cutaneous squamous cell carcinoma a useful and reliable source for patients? ⁶²	Reinhardt L...Berking C	36464812	2022
12	Rate and Characteristics of Incompletely Excised Cutaneous Squamous Cell Carcinoma: A Dermatological Daily Practice Multicenter Prospective Cohort Study. ⁶²	van Lee CB...van den Bos RR	36194767	2022
13	DANGER: what clinicians need to know about aggressive head and neck cutaneous squamous cell carcinoma. ⁶²	Tjahjono R...Palme CE	36463501	2022
14	A phase 2 study of first-line nivolumab in patients with locally advanced or metastatic cutaneous squamous-cell carcinoma. ⁶²	Munhoz RR...de Castro G	36274573	2022
15	Defining the Molecular Landscape of Cancer-Associated Stroma in Cutaneous Squamous Cell Carcinoma. ⁶²	Beebe E...Feldmeyer L	35850206	2022
16	Lack of documentation of lymph node examination in patients with squamous cell carcinoma of the lower lip. ⁶²	Eickstaedt JB...Xu YG	34562138	2022
17	Addendum: Mutually exclusive lymphangiogenesis or perineural infiltration in human skin squamous-cell carcinoma. ⁶²	Schaller J...Schaeuble K	36473116	2022
18	Cutaneous horn due to cutaneous squamous cell carcinoma. ⁶²	Zhang LW...Chen T	36379697	2022
19	Value of permanent pathology for debulk and Mohs specimens during Mohs micrographic surgery for cutaneous squamous cell carcinoma: A retrospective cohort study. ⁶²	Nemeh MN...Nijhawan RI	35753550	2022
20	A case of head and neck cutaneous squamous cell carcinoma highlighting aggressive perineural features. ⁶²	Kalil GH...Jefferson GD	36189160	2022
21	Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma. ⁶²	Ascierto PA...Schadendorf D	36455990	2022
22	[Cutaneous squamous cell carcinoma of the head and neck]. ⁶²	Deutsch J...Delank KW	36455599	2022
23	Immune status does not independently influence cutaneous squamous cell carcinoma metastasis and death when stratified by tumor stage: A dual-center retrospective cohort analysis of primary N0 disease. ⁶²	O'Connor DM...Ruiz ES	36063987	2022
24	Towards less mutilating treatments in patients with advanced non-melanoma skin cancers by earlier use of immune checkpoint inhibitors. ⁶²	Hooiveld-Noeken JS...Jalving M	36257534	2022
25	Characterizing Skin Cancer in Transplant Recipients by Fitzpatrick Skin Phototype. ⁶²	Shope CN...Lee LW	36469283	2022
26	Prevalence of 13 polyomaviruses in actinic keratosis and matched healthy skin samples of immunocompetent individuals. ⁶²	Dona MG...Di Bonito P	36457033	2022
27	Comparison of reflectance confocal microscopy and line-field optical coherence tomography for the identification of keratinocyte skin tumours. ⁶²	Cinotti E...Rubegni P	36424847	2022
28	An Epidemiological Update on Indoor Tanning and the Risk of Skin Cancers. ⁶²	Dessinioti C...Stratigos AJ	36421352	2022
29	Features and clinical significance of tertiary lymphoid structure in cutaneous squamous cell carcinoma. ⁶²	Wu YH...Wang XL	35881141	2022
30	Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients. ⁶²	Hooper PB...Litchman GH	36073945	2022
31	S1-Guideline: Microscopically controlled surgery. ⁶²	Kofler L...Muller CSL	36448272	2022
32	Genetically Predicted Serum Vitamin C Levels and Cutaneous Squamous Cell Carcinoma Risk. ⁶²	Kim Y...Asgari MM	36343677	2022
33	Cutaneous squamous cell carcinoma in an autosomal-recessive Adams-Oliver syndrome patient with a novel frameshift pathogenic variant in the EOGT gene. ⁶²	Lukas ML...Jochen R	36059114	2022
34	Cutaneous Squamous Cell Carcinoma and Mortality in End-Stage Renal Disease. ⁶²	Jung J...Bollag WB	36403674	2022
35	Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer. ⁶²	Nguyen JH...Al-Huniti N	36251220	2022
36	Follow-up of Patients With Keratinocyte Carcinoma: A Systematic Review of Clinical Practice Guidelines. ⁶²	Mirali S...Chan AW	36322063	2022
37	Complete response of locally advanced cutaneous squamous cell carcinoma of the eyelid to topical imiquimod 3.75. ⁶²	Toso F...Borroni RG	36066074	2022
38	Recurrent bilateral cutaneous squamous cell carcinoma arising within hypertrophic lichen planus with metastasis while on cemiplimab. ⁶²	Leeolou MC...Chang ALS	36193242	2022
39	Locally Advanced Cutaneous Squamous Cell Carcinoma Treated With Immunotherapy in a Dermatology Department. ⁶²	Navarro Navarro I...Linares Barrios M	36370835	2022
40	Modelling cutaneous squamous cell carcinoma for laboratory research. ⁶²	Kumah E...Bibee K	36373888	2022
41	In-transit Metastases of Cutaneous Squamous Cell Carcinoma: A Single Institution Case Series. ⁶²	Klein JC...Nijhawan RI	36403751	2022
42	Humoral hypercalcaemia of malignancy associated with a gigantic cutaneous squamous cell carcinoma. ⁶²	Elantably D...Alkrekshi A	36323452	2022
43	Anti PD-1 Checkpoint Inhibitor As a First-Line Treatment for Advanced Cutaneous Squamous Cell Carcinoma. ⁶²	Bopota K...Borumandi F	36441840	2022
44	Twist1 as a target for prevention of cutaneous squamous cell carcinoma. ⁶²	Wang T...DiGiovanni J	36373194	2022
45	Alkannin exerts antitumor properties in cutaneous squamous cell carcinoma by inducing apoptosis and shifting the M1/M2 polarization of tumor-associated macrophages by upregulating PTEN. ⁶²	Zhang ZZ...Sun SQ	36367154	2022
46	Characterisation of the immune microenvironment of cutaneous squamous cell carcinoma in immunosuppression. ⁶²	Rajesh A...Hibma M	35861124	2022
47	Chemoprevention of cutaneous squamous cell carcinoma and its precursors in solid organ transplant recipients using topical sirolimus: A randomized, double-blind, placebo-controlled pilot trial. ⁶²	Chong S...Khosrotehrani K	35219749	2022
48	Cutaneous Squamous Cell Carcinoma With Orbital Extension. ⁶²	Park KS...Liu CY	36201188	2022
49	Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: A systemic review and meta-analysis. ⁶²	Zhang H...Chen J	36329570	2022
50	The Potentiation of Radiosensitization by Concomitant Treatment With Radiation Therapy and a PDL-1 Inhibitor in Cutaneous Squamous Cell Carcinoma. ⁶²	Fadel CA...Caudell MD	36131995	2022

Sources

Genes for Skin Squamous Cell Carcinoma

Genes related to Skin Squamous Cell Carcinoma (0 elite genes):

(show all 33)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	150	Experimental evidence: Expression ³⁷	27067026
2	KNSTRN	Kinetochore Localized Astrin (SPAG5) Binding Protein	Protein Coding	36.28	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Summaries (show sections)	26619011
3	TP53	Tumor Protein P53	Protein Coding	31.5	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
4	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	31.5	Likely pathogenic ⁵ DISEASES inferred ¹⁴	22256804 22726224 25157968 (more) 26619011
5	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	31.09	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
6	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	30.5	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
7	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	30.22	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
8	STK19	Serine/Threonine Kinase 19	Protein Coding	29.01	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
9	RAC1	Rac Family Small GTPase 1	Protein Coding	27.87	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
10	BCL2L12	BCL2 Like 12	Protein Coding	25	Likely pathogenic ⁵	26619011
11	CRNKL1	Crooked Neck Pre-MRNA Splicing Factor 1	Protein Coding	25	Likely pathogenic ⁵	26619011
12	LRRC56	Leucine Rich Repeat Containing 56	Protein Coding	25	Likely pathogenic ⁵	22256804 22726224 25157968 (more) 26619011
13	FAT2	FAT Atypical Cadherin 2	Protein Coding	11.01	DISEASES inferred ¹⁴ GeneCards inferred via : Expressions (show sections)
14	MIR21	MicroRNA 21	RNA Gene	6.83	DISEASES inferred ¹⁴ ¹⁴
15	KDM4C	Lysine Demethylase 4C	Protein Coding	6.81	DISEASES inferred ¹⁴ ¹⁴
16	RAF1	Raf-1 Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	6.52	DISEASES inferred ¹⁴
17	MSH2	MutS Homolog 2	Protein Coding	6.47	DISEASES inferred ¹⁴
18	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	6.1	DISEASES inferred ¹⁴
19	MLH1	MutL Homolog 1	Protein Coding	6.06	DISEASES inferred ¹⁴
20	MSH6	MutS Homolog 6	Protein Coding	5.99	DISEASES inferred ¹⁴
21	EGFR	Epidermal Growth Factor Receptor	Protein Coding	5.92	DISEASES inferred ¹⁴
22	ARAF	A-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	5.8	DISEASES inferred ¹⁴
23	MAP2K1	Mitogen-Activated Protein Kinase Kinase 1	Protein Coding	5.8	DISEASES inferred ¹⁴
24	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	5.79	DISEASES inferred ¹⁴
25	IVL	Involucrin	Protein Coding	5.72	DISEASES inferred ¹⁴
26	PMS2	PMS1 Homolog 2, Mismatch Repair System Component	Protein Coding	5.72	DISEASES inferred ¹⁴
27	KRT10	Keratin 10	Protein Coding	5.69	DISEASES inferred ¹⁴
28	CDH1	Cadherin 1	Protein Coding	5.63	DISEASES inferred ¹⁴
29	KRT5	Keratin 5	Protein Coding	5.62	DISEASES inferred ¹⁴
30	KRT14	Keratin 14	Protein Coding	5.6	DISEASES inferred ¹⁴
31	CTNNB1	Catenin Beta 1	Protein Coding	5.59	DISEASES inferred ¹⁴
32	PTEN	Phosphatase And Tensin Homolog	Protein Coding	5.55	DISEASES inferred ¹⁴
33	CCND1	Cyclin D1	Protein Coding	5.5	DISEASES inferred ¹⁴

Sources

Variations for Skin Squamous Cell Carcinoma

ClinVar genetic disease variations for Skin Squamous Cell Carcinoma:

⁵ (show top 50) (show all 107)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	KNSTRN	NM_033286.4(KNSTRN):c.71C>T (p.Ser24Phe)	SNV	Likely Pathogenic	376441	rs868438023	GRCh37: 15:40675107-40675107 GRCh38: 15:40382906-40382906
2	RAC1	NM_006908.5(RAC1):c.86C>T (p.Pro29Leu)	SNV	Likely Pathogenic	376512	rs1057519948	GRCh37: 7:6426893-6426893 GRCh38: 7:6387262-6387262
3	CRNKL1	NM_001278628.2(CRNKL1):c.-101C>T	SNV	Likely Pathogenic	376389	rs1057519885	GRCh37: 20:20033087-20033087 GRCh38: 20:20052443-20052443
4	RAC1	NM_006908.5(RAC1):c.85C>A (p.Pro29Thr)	SNV	Likely Pathogenic	376513	rs1057519874	GRCh37: 7:6426892-6426892 GRCh38: 7:6387261-6387261
5	CDKN2A	NM_000077.5(CDKN2A):c.341C>A (p.Pro114His)	SNV	Likely Pathogenic	376383	rs121913386	GRCh37: 9:21971017-21971017 GRCh38: 9:21971018-21971018
6	CDKN2A	NM_000077.5(CDKN2A):c.340C>A (p.Pro114Thr)	SNV	Likely Pathogenic	376382	rs104894104	GRCh37: 9:21971018-21971018 GRCh38: 9:21971019-21971019
7	BRAF	NM_004333.6(BRAF):c.1405G>C (p.Gly469Arg)	SNV	Likely Pathogenic	13970	rs121913357	GRCh37: 7:140481403-140481403 GRCh38: 7:140781603-140781603
8	BRAF	NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala)	SNV	Likely Pathogenic	13971	rs121913355	GRCh37: 7:140481402-140481402 GRCh38: 7:140781602-140781602
9	HRAS, LRRC56	NM_005343.4(HRAS):c.37G>A (p.Gly13Ser)	SNV	Likely Pathogenic	376323	rs104894228	GRCh37: 11:534286-534286 GRCh38: 11:534286-534286
10	CDKN2A	NM_000077.5(CDKN2A):c.150G>T (p.Gln50His)	SNV	Likely Pathogenic	376384	rs1057519882	GRCh37: 9:21974677-21974677 GRCh38: 9:21974678-21974678
11	ERBB2	NM_004448.4(ERBB2):c.929C>T (p.Ser310Phe)	SNV	Likely Pathogenic	376189	rs1057519816	GRCh37: 17:37868208-37868208 GRCh38: 17:39711955-39711955
12	HRAS, LRRC56	NM_005343.4(HRAS):c.38G>T (p.Gly13Val)	SNV	Likely Pathogenic	180848	rs104894226	GRCh37: 11:534285-534285 GRCh38: 11:534285-534285
13	BRAF	NM_004333.6(BRAF):c.1406G>T (p.Gly469Val)	SNV	Likely Pathogenic	44803	rs121913355	GRCh37: 7:140481402-140481402 GRCh38: 7:140781602-140781602
14	RAC1	NM_006908.5(RAC1):c.85C>T (p.Pro29Ser)	SNV	Likely Pathogenic	376362	rs1057519874	GRCh37: 7:6426892-6426892 GRCh38: 7:6387261-6387261
15	CDKN2A	NM_000077.5(CDKN2A):c.247C>G (p.His83Asp)	SNV	Likely Pathogenic	376380	rs121913385	GRCh37: 9:21971111-21971111 GRCh38: 9:21971112-21971112
16	HRAS, LRRC56	NM_005343.4(HRAS):c.183G>T (p.Gln61His)	SNV	Likely Pathogenic	376318	rs121913496	GRCh37: 11:533873-533873 GRCh38: 11:533873-533873
17	HRAS, LRRC56	NM_005343.4(HRAS):c.182A>T (p.Gln61Leu)	SNV	Likely Pathogenic	376033	rs121913233	GRCh37: 11:533874-533874 GRCh38: 11:533874-533874
18	ERBB2	NM_004448.4(ERBB2):c.929C>A (p.Ser310Tyr)	SNV	Likely Pathogenic	376188	rs1057519816	GRCh37: 17:37868208-37868208 GRCh38: 17:39711955-39711955
19	TP53	NM_000546.6(TP53):c.856G>C (p.Glu286Gln)	SNV	Likely Pathogenic	376591	rs786201059	GRCh37: 17:7577082-7577082 GRCh38: 17:7673764-7673764
20	TP53	NM_000546.6(TP53):c.746G>T (p.Arg249Met)	SNV	Likely Pathogenic	376653	rs587782329	GRCh37: 17:7577535-7577535 GRCh38: 17:7674217-7674217
21	TP53	NM_000546.6(TP53):c.722C>A (p.Ser241Tyr)	SNV	Likely Pathogenic	376663	rs28934573	GRCh37: 17:7577559-7577559 GRCh38: 17:7674241-7674241
22	TP53	NM_000546.6(TP53):c.842A>C (p.Asp281Ala)	SNV	Likely Pathogenic	376589	rs587781525	GRCh37: 17:7577096-7577096 GRCh38: 17:7673778-7673778
23	TP53	NM_000546.6(TP53):c.706T>G (p.Tyr236Asp)	SNV	Likely Pathogenic	142183	rs587782289	GRCh37: 17:7577575-7577575 GRCh38: 17:7674257-7674257
24	TP53	NM_000546.6(TP53):c.721T>C (p.Ser241Pro)	SNV	Likely Pathogenic	376664	rs1057520002	GRCh37: 17:7577560-7577560 GRCh38: 17:7674242-7674242
25	TP53	NM_000546.6(TP53):c.809T>G (p.Phe270Cys)	SNV	Likely Pathogenic	376597	rs1057519986	GRCh37: 17:7577129-7577129 GRCh38: 17:7673811-7673811
26	TP53	NM_000546.6(TP53):c.857A>T (p.Glu286Val)	SNV	Likely Pathogenic	376592	rs1057519985	GRCh37: 17:7577081-7577081 GRCh38: 17:7673763-7673763
27	TP53	NM_000546.6(TP53):c.857A>G (p.Glu286Gly)	SNV	Likely Pathogenic	376590	rs1057519985	GRCh37: 17:7577081-7577081 GRCh38: 17:7673763-7673763
28	TP53	NM_000546.6(TP53):c.647T>G (p.Val216Gly)	SNV	Likely Pathogenic	376671	rs1057520004	GRCh37: 17:7578202-7578202 GRCh38: 17:7674884-7674884
29	HRAS, LRRC56	NM_005343.4(HRAS):c.37G>C (p.Gly13Arg)	SNV	Likely Pathogenic	35554	rs104894228	GRCh37: 11:534286-534286 GRCh38: 11:534286-534286
30	TP53	NM_000546.6(TP53):c.373A>C (p.Thr125Pro)	SNV	Likely Pathogenic	376666	rs1057520003	GRCh37: 17:7579314-7579314 GRCh38: 17:7675996-7675996
31	TP53	NM_000546.6(TP53):c.841G>T (p.Asp281Tyr)	SNV	Likely Pathogenic	376585	rs764146326	GRCh37: 17:7577097-7577097 GRCh38: 17:7673779-7673779
32	TP53	NM_000546.6(TP53):c.638G>T (p.Arg213Leu)	SNV	Likely Pathogenic	376650	rs587778720	GRCh37: 17:7578211-7578211 GRCh38: 17:7674893-7674893
33	TP53	NM_000546.6(TP53):c.839G>T (p.Arg280Ile)	SNV	Likely Pathogenic	161517	rs121912660	GRCh37: 17:7577099-7577099 GRCh38: 17:7673781-7673781
34	TP53	NM_000546.6(TP53):c.815T>A (p.Val272Glu)	SNV	Likely Pathogenic	376673	rs876660333	GRCh37: 17:7577123-7577123 GRCh38: 17:7673805-7673805
35	TP53	NM_000546.6(TP53):c.810T>G (p.Phe270Leu)	SNV	Likely Pathogenic	376595	rs1057519987	GRCh37: 17:7577128-7577128 GRCh38: 17:7673810-7673810
36	TP53	NM_000546.6(TP53):c.374C>A (p.Thr125Lys)	SNV	Likely Pathogenic	216465	rs786201057	GRCh37: 17:7579313-7579313 GRCh38: 17:7675995-7675995
37	TP53	NM_000546.6(TP53):c.857A>C (p.Glu286Ala)	SNV	Likely Pathogenic	376593	rs1057519985	GRCh37: 17:7577081-7577081 GRCh38: 17:7673763-7673763
38	HRAS, LRRC56	NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)	SNV	Likely Pathogenic	12613	rs104894229	GRCh37: 11:534289-534289 GRCh38: 11:534289-534289
39	HRAS, LRRC56	NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)	SNV	Likely Pathogenic	12603	rs104894230	GRCh37: 11:534288-534288 GRCh38: 11:534288-534288
40	HRAS, LRRC56	NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)	SNV	Likely Pathogenic	12606	rs104894228	GRCh37: 11:534286-534286 GRCh38: 11:534286-534286
41	TP53	NM_000546.6(TP53):c.722C>T (p.Ser241Phe)	SNV	Likely Pathogenic	12359	rs28934573	GRCh37: 17:7577559-7577559 GRCh38: 17:7674241-7674241
42	TP53	NM_000546.6(TP53):c.647T>A (p.Val216Glu)	SNV	Likely Pathogenic	376672	rs1057520004	GRCh37: 17:7578202-7578202 GRCh38: 17:7674884-7674884
43	TP53	NM_000546.6(TP53):c.845G>C (p.Arg282Pro)	SNV	Likely Pathogenic	376659	rs730882008	GRCh37: 17:7577093-7577093 GRCh38: 17:7673775-7673775
44	TP53	NM_000546.6(TP53):c.535C>T (p.His179Tyr)	SNV	Likely Pathogenic	127815	rs587780070	GRCh37: 17:7578395-7578395 GRCh38: 17:7675077-7675077
45	TP53	NM_000546.6(TP53):c.832C>G (p.Pro278Ala)	SNV	Likely Pathogenic	376645	rs17849781	GRCh37: 17:7577106-7577106 GRCh38: 17:7673788-7673788
46	TP53	NM_000546.6(TP53):c.841G>C (p.Asp281His)	SNV	Likely Pathogenic	376588	rs764146326	GRCh37: 17:7577097-7577097 GRCh38: 17:7673779-7673779
47	TP53	NM_000546.6(TP53):c.638G>C (p.Arg213Pro)	SNV	Likely Pathogenic	231214	rs587778720	GRCh37: 17:7578211-7578211 GRCh38: 17:7674893-7674893
48	TP53	NM_000546.6(TP53):c.638G>A (p.Arg213Gln)	SNV	Likely Pathogenic	135359	rs587778720	GRCh37: 17:7578211-7578211 GRCh38: 17:7674893-7674893
49	TP53	NM_000546.6(TP53):c.537T>G (p.His179Gln)	SNV	Likely Pathogenic	376607	rs876660821	GRCh37: 17:7578393-7578393 GRCh38: 17:7675075-7675075
50	TP53	NM_000546.6(TP53):c.746G>A (p.Arg249Lys)	SNV	Likely Pathogenic	142241	rs587782329	GRCh37: 17:7577535-7577535 GRCh38: 17:7674217-7674217

Cosmic variations for Skin Squamous Cell Carcinoma:

⁸ (show top 50) (show all 15557)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM108405939	ZNF668	skin,NS,carcinoma,squamous cell carcinoma	c.316C>T	p.P106S	16:31064213-31064213	19
2	COSM131595377	ZNF668	skin,NS,carcinoma,squamous cell carcinoma	c.947C>T	p.S316L	16:31062050-31062050	19
3	COSM101742625	ZNF668	skin,NS,carcinoma,squamous cell carcinoma	c.878C>T	p.S293L	16:31062050-31062050	19
4	COSM131595368	ZNF668	skin,NS,carcinoma,squamous cell carcinoma	c.1886C>T	p.P629L	16:31061111-31061111	19
5	COSM87498632	ZNF668	skin,NS,carcinoma,squamous cell carcinoma	c.247C>T	p.P83S	16:31064213-31064213	19
6	COSM101742795	ZNF668	skin,NS,carcinoma,squamous cell carcinoma	c.247C>T	p.P83S	16:31064213-31064213	19
7	COSM133260761	ZNF668	skin,NS,carcinoma,squamous cell carcinoma	c.878C>T	p.S293L	16:31062050-31062050	19
8	COSM132355968	ZNF668	skin,NS,carcinoma,squamous cell carcinoma	c.1817C>T	p.P606L	16:31061111-31061111	19
9	COSM132355981	ZNF668	skin,NS,carcinoma,squamous cell carcinoma	c.878C>T	p.S293L	16:31062050-31062050	19
10	COSM131595526	ZNF668	skin,NS,carcinoma,squamous cell carcinoma	c.316C>T	p.P106S	16:31064213-31064213	19
11	COSM87498178	ZNF668	skin,NS,carcinoma,squamous cell carcinoma	c.1817C>T	p.P606L	16:31061111-31061111	19
12	COSM101742614	ZNF668	skin,NS,carcinoma,squamous cell carcinoma	c.1817C>T	p.P606L	16:31061111-31061111	19
13	COSM133260750	ZNF668	skin,NS,carcinoma,squamous cell carcinoma	c.1817C>T	p.P606L	16:31061111-31061111	19
14	COSM133260941	ZNF668	skin,NS,carcinoma,squamous cell carcinoma	c.247C>T	p.P83S	16:31064213-31064213	19
15	COSM108405783	ZNF668	skin,NS,carcinoma,squamous cell carcinoma	c.1886C>T	p.P629L	16:31061111-31061111	19
16	COSM108405799	ZNF668	skin,NS,carcinoma,squamous cell carcinoma	c.947C>T	p.S316L	16:31062050-31062050	19
17	COSM132356152	ZNF668	skin,NS,carcinoma,squamous cell carcinoma	c.247C>T	p.P83S	16:31064213-31064213	19
18	COSM87498195	ZNF668	skin,NS,carcinoma,squamous cell carcinoma	c.878C>T	p.S293L	16:31062050-31062050	19
19	COSM101590418	ZMYM2	skin,NS,carcinoma,squamous cell carcinoma	c.946C>T	p.Q316*	13:20002948-20002948	19
20	COSM143109510	ZMYM2	skin,NS,carcinoma,squamous cell carcinoma	c.946C>T	p.Q316*	13:20002948-20002948	19
21	COSM101612017	ZMYM2	skin,NS,carcinoma,squamous cell carcinoma	c.946C>T	p.Q316*	13:20002948-20002948	19
22	COSM107139107	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.683A>C	p.K228T	3:147395971-147395971	19
23	COSM101870708	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.522C>T	p.F174=	3:147396018-147396018	19
24	COSM129142467	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.672C>T	p.F224=	3:147396018-147396018	19
25	COSM118697764	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.71-4725A>C	p.?	3:147395971-147395971	19
26	COSM115494047	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.569A>C	p.K190T	3:147395971-147395971	19
27	COSM118700792	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.71-4772C>T	p.?	3:147396018-147396018	19
28	COSM115497576	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.282C>G	p.A94=	3:147396258-147396258	19
29	COSM129137619	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.135G>A	p.K45=	3:147403964-147403964	19
30	COSM129143394	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.1026G>C	p.P342=	3:147391059-147391059	19
31	COSM115492982	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.-15-1152G>A	p.?	3:147403964-147403964	19
32	COSM107143716	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.396C>G	p.A132=	3:147396258-147396258	19
33	COSM129143406	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.432C>G	p.A144=	3:147396258-147396258	19
34	COSM101872056	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.282C>G	p.A94=	3:147396258-147396258	19
35	COSM120258678	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.-16G>A	p.?	3:147403964-147403964	19
36	COSM101866693	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.569A>C	p.K190T	3:147395971-147395971	19
37	COSM101864973	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.-15-1152G>A	p.?	3:147403964-147403964	19
38	COSM115497565	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.876G>C	p.P292=	3:147391059-147391059	19
39	COSM120264120	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.876G>C	p.P292=	3:147391059-147391059	19
40	COSM107142798	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.636C>T	p.F212=	3:147396018-147396018	19
41	COSM101867690	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.314T>G	p.V105G	3:147396226-147396226	19
42	COSM120260940	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.314T>G	p.V105G	3:147396226-147396226	19
43	COSM118702064	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.71-5012C>G	p.?	3:147396258-147396258	19
44	COSM129140070	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.464T>G	p.V155G	3:147396226-147396226	19
45	COSM120260164	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.569A>C	p.K190T	3:147395971-147395971	19
46	COSM118698551	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.71-4980T>G	p.?	3:147396226-147396226	19
47	COSM101872044	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.876G>C	p.P292=	3:147391059-147391059	19
48	COSM118702056	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.258G>C	p.P86=	3:147391059-147391059	19
49	COSM129139322	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.719A>C	p.K240T	3:147395971-147395971	19
50	COSM107143709	ZIC4	skin,NS,carcinoma,squamous cell carcinoma	c.990G>C	p.P330=	3:147391059-147391059	19

Sources

Expression for Skin Squamous Cell Carcinoma

Search GEO for disease gene expression data for Skin Squamous Cell Carcinoma.

Sources

Pathways for Skin Squamous Cell Carcinoma

Pathways related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 101)

#	Super pathways	Score	Top Affiliating Genes
1	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.82	BRAF CDKN2A ERBB2 HRAS MLH1 MSH2
2	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.75	TP53 RAF1 RAC1 NRAS HRAS ERBB2
3	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.5	TP53 RAF1 RAC1 NRAS MSH6 HRAS
4	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	13.12	TP53 RAF1 RAC1 NRAS HRAS BRAF
5	Beta-Adrenergic Signaling ⁶⁴ Show member pathways CDK5 Pathway ⁶⁴ Erythropoietin Pathway ⁶⁴ Insulin Pathway ⁷⁰ Insulin Receptor Pathway ⁶⁴	12.94	RAF1 RAC1 NRAS HRAS BRAF
6	NFAT and Cardiac Hypertrophy ⁶⁴ Show member pathways IGF1R Signaling ⁶⁴ Signaling Involved in Cardiac Hypertrophy ⁶⁴	12.92	RAF1 RAC1 NRAS HRAS ERBB2 BRAF
7	IL-9 Signaling Pathways ⁶⁵ Show member pathways Adipocytokines and Insulin Signaling ⁶⁵ Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶⁵ Development Thrombopoietin-regulated cell processes ²² IL-15 Signaling Pathways ⁶⁵ IL-2 Signaling Pathways ⁶⁵ IL-21 Signaling Pathways ⁶⁵ IL-4 Pathway ⁶⁴ IL-4 Signaling Pathways ⁶⁵ IL-7 Signaling Pathways ⁶⁵ IL-9 Pathway ⁶⁴ Immune response IL-9 signaling pathway ²² Interleukin-9 signaling ⁶⁶	12.91	RAF1 RAC1 NRAS HRAS BRAF
8	CCR5 Pathway in Macrophages ⁶⁴ Show member pathways Androgen Signaling ⁶⁴ Chemokine Signaling ⁶⁴ Chemokine signaling pathway ⁷⁴	12.91	RAF1 RAC1 NRAS HRAS BRAF
9	Development Angiotensin activation of ERK ²² Show member pathways Cell adhesion Integrin inside-out signaling ²² Development ACM2 and ACM4 activation of ERK ²² Development Angiotensin signaling via PYK2 ²² Development EDNRB signaling ²² Development EPO-induced MAPK pathway ²² Development G-Proteins mediated regulation MARK-ERK signaling ²² Signal transduction IP3 signaling ²²	12.89	RAF1 RAC1 NRAS HRAS BRAF
10	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.88	BRAF ERBB2 HRAS NRAS RAC1
11	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.88	TP53 RAF1 RAC1 NRAS HRAS BRAF
12	fMLP Pathway ⁶⁴ Show member pathways CXCR4 Pathway ⁶⁴ Huntington's Disease Pathway ⁶⁴ Internalin Pathway ⁶⁴ Signal transduction Activation of PKC via G-Protein coupled receptor ²²	12.82	HRAS NRAS RAC1 RAF1 TP53
13	MAPK-Erk Pathway ⁶⁷ Show member pathways Actin Dynamics Signaling Pathway ⁶⁷ G Protein-coupled Receptors Signaling ⁶⁷	12.79	RAF1 RAC1 NRAS HRAS BRAF
14	TCR Signaling (Qiagen) ⁶⁴ Show member pathways Fc-EpsilonRI Pathway ⁶⁴ ITK and TCR Signaling ⁶⁴ PDGF Pathway ⁶⁴ PKC-Theta Pathway ⁶⁴	12.75	TP53 RAF1 RAC1 NRAS MSH6 MSH2
15	CNTF Signaling ⁶⁴ Show member pathways Activation of the AP-1 family of transcription factors ⁶⁶ FLT3 Signaling ⁶⁴ G-protein signaling Ras family GTPases in kinase cascades (scheme) ²² Host-pathogen interaction of human coronaviruses - MAPK signaling ⁷⁴ IL-3 Pathway ⁶⁴ Immune response Oncostatin M signaling via MAPK in human cells ²² Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells ⁷⁴ MAPK cascade ⁷⁴ Nur77-Induced AICD in Macrophage ⁶⁴ OSM Pathway ⁶⁴	12.72	RAF1 RAC1 NRAS HRAS BRAF
16	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.72	TP53 RAF1 NRAS HRAS BRAF
17	G-Beta Gamma Signaling ⁶⁴ Show member pathways CRHR Pathway ⁶⁴ GHRH Signaling ⁶⁴	12.71	RAF1 NRAS HRAS CDKN2A BRAF
18	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.62	TP53 RAC1 NRAS MSH2 HRAS ERBB2
19	DNA Damage ³	12.56	TP53 MSH6 MSH2 MLH1 CDKN2A
20	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.48	TP53 NRAS HRAS ERBB2
21	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.46	RAF1 RAC1 NRAS HRAS
22	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.45	RAF1 RAC1 HRAS BRAF
23	Development FGFR signaling pathway ²² Show member pathways Development FGF-family signaling ²² Development Flt3 signaling ²² FGF Pathway ⁶⁴	12.45	RAF1 RAC1 NRAS HRAS
24	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.44	TP53 RAF1 RAC1 HRAS ERBB2 BRAF
25	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.43	TP53 RAF1 NRAS HRAS ERBB2 BRAF
26	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.42	RAF1 RAC1 NRAS HRAS ERBB2 BRAF
27	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.38	RAF1 RAC1 HRAS ERBB2
28	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.37	TP53 RAF1 RAC1 HRAS
29	B Cell Receptor Signaling Pathway ⁶⁷ Show member pathways T Cell Receptor Signaling Pathway ⁶⁷	12.37	RAF1 RAC1 NRAS HRAS
30	MAPK signaling pathway ⁷⁴	12.34	BRAF HRAS NRAS RAC1 RAF1 TP53
31	Focal adhesion ⁷⁴	12.33	RAF1 RAC1 HRAS ERBB2 BRAF
32	Ras signaling ⁷⁴	12.3	RAF1 RAC1 NRAS HRAS
33	Integrin-mediated cell adhesion ⁷⁴ Show member pathways HGF Pathway ⁶⁴	12.3	RAF1 RAC1 NRAS HRAS BRAF
34	VEGF Signaling Pathway ⁶⁰ ⁶⁷ Show member pathways Nanoparticle-mediated activation of receptor signaling ⁷⁴ TGF-beta Signaling ⁶⁷	12.27	RAF1 RAC1 NRAS HRAS
35	Colorectal Cancer Metastasis ⁶⁴	12.23	TP53 MSH6 MSH2 MLH1 BRAF
36	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.23	TP53 RAF1 NRAS HRAS ERBB2 BRAF
37	Signaling by PTK6 ⁶⁶ Show member pathways PTK6 Activates STAT3 ⁶⁶ PTK6 Down-Regulation ⁶⁶ PTK6 Expression ⁶⁶ PTK6 promotes HIF1A stabilization ⁶⁶ PTK6 Regulates Proteins Involved in RNA Processing ⁶⁶ PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases ⁶⁶ PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 ⁶⁶ Signaling by Non-Receptor Tyrosine Kinases ⁶⁶	12.21	ERBB2 HRAS NRAS RAC1
38	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.2	TP53 RAF1 HRAS CDKN2A
39	Regulation of actin cytoskeleton ⁷⁴	12.2	RAF1 RAC1 NRAS BRAF
40	Oncogenic MAPK signaling ⁶⁶ Show member pathways Signaling by BRAF and RAF1 fusions ⁶⁶	12.19	RAF1 NRAS HRAS BRAF
41	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.19	TP53 RAF1 RAC1 NRAS HRAS ERBB2
42	Integrated breast cancer pathway ⁷⁴	12.17	BRAF MSH2 MSH6 RAC1 TP53
43	CCR3 Pathway in Eosinophils ⁶⁴ Show member pathways VEGF and S-1P Signaling ⁶⁴	12.14	RAF1 RAC1 NRAS HRAS BRAF
44	GDNF signaling ⁷⁴	12.12	RAF1 RAC1 NRAS BRAF
45	mTOR Signaling ⁶⁵	12.12	TP53 RAF1 RAC1 ERBB2 BRAF
46	G12-G13 in Cellular Signaling ⁶⁴	12.08	HRAS NRAS RAC1 RAF1
47	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	12.07	TP53 RAF1 ERBB2 BRAF
48	Gastrin signaling pathway ⁷⁴	12.02	RAF1 RAC1 HRAS CDKN2A
49	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.02	TP53 STK19 RAF1 RAC1 NRAS MSH6
50	S-1P Stimulated Signaling ⁶⁴	12	RAF1 RAC1 NRAS BRAF

Sources

GO Terms for Skin Squamous Cell Carcinoma

Cellular components related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mismatch repair complex	GO:0032300	9.13	MSH2 MLH1
2	MutSalpha complex	GO:0032301	8.92	MSH6 MSH2

Biological processes related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 17)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	10.16	TP53 MIR21 HRAS ERBB2 CDKN2A BRAF
2	MAPK cascade	GO:0000165	10.14	BRAF HRAS NRAS RAF1
3	Ras protein signal transduction	GO:0007265	10.01	TP53 NRAS HRAS CDKN2A
4	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	9.97	MSH6 MSH2 MLH1
5	intrinsic apoptotic signaling pathway	GO:0097193	9.95	TP53 MSH6 HRAS
6	mismatch repair	GO:0006298	9.91	MLH1 MSH2 MSH6
7	positive regulation of helicase activity	GO:0051096	9.85	MSH6 MSH2
8	cellular response to gamma radiation	GO:0071480	9.85	TP53 MIR21 HRAS
9	determination of adult lifespan	GO:0008340	9.85	TP53 MSH6 MSH2
10	positive regulation of isotype switching to IgA isotypes	GO:0048298	9.81	MSH2 MLH1
11	isotype switching	GO:0045190	9.8	MSH6 MSH2 MLH1
12	negative regulation of immature T cell proliferation in thymus	GO:0033088	9.7	ERBB2 CDKN2A
13	maintenance of DNA repeat elements	GO:0043570	9.67	MSH6 MSH2
14	somatic hypermutation of immunoglobulin genes	GO:0016446	9.63	MSH6 MSH2 MLH1
15	positive regulation of protein phosphorylation	GO:0001934	9.61	RAF1 RAC1 MIR21 HRAS ERBB2 BRAF
16	somatic recombination of immunoglobulin genes involved in immune response	GO:0002204	9.43	MLH1 MSH2
17	somatic recombination of immunoglobulin gene segments	GO:0016447	9.02	MSH6 MSH2 MLH1

Molecular functions related to Skin Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	enzyme binding	GO:0019899	10.1	KDM4C MLH1 MSH2 MSH6 RAC1 RAF1
2	G protein activity	GO:0003925	9.91	RAC1 NRAS HRAS
3	ATP-dependent DNA damage sensor activity	GO:0140664	9.8	MSH6 MSH2 MLH1
4	MutLalpha complex binding	GO:0032405	9.78	MSH6 MSH2
5	oxidized purine DNA binding	GO:0032357	9.76	MSH6 MSH2
6	single guanine insertion binding	GO:0032142	9.71	MSH6 MSH2
7	single thymine insertion binding	GO:0032143	9.67	MSH6 MSH2
8	nucleotide binding	GO:0000166	9.65	STK19 RAF1 RAC1 NRAS MSH6 MSH2
9	mismatched DNA binding	GO:0030983	9.55	MSH6 MSH2 MLH1
10	guanine/thymine mispair binding	GO:0032137	9.1	MSH6 MSH2 MLH1